Back to SRLS
Robbins Umeda LLP Announces an Investigation of SeraCare Life Sciences, Inc.

Shareholder rights firm Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by members of the board of directors of SeraCare Life Sciences, Inc. (NASDAQ:SRLS) in connection with their efforts to sell the company to Linden Capital Partners. Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Gregory E. Del Gaizo at (800) 350-6003, info@robbinsumeda.com, or via the shareholder information form on the firm's website.

On February 13, 2012, SeraCare announced that it has entered into a definitive agreement to be acquired by an affiliate of Linden Capital Partners, a Chicago-based private equity firm. According to the terms of the agreement, SeraCare shareholders will receive $4.00 for each share of the company they own. The agreement was unanimously approved by SeraCare's board of directors. The transaction is expected to close in the second quarter of calendar year 2012.

Robbins Umeda LLP's investigation focuses on whether SeraCare's board is undertaking a fair process to obtain maximum value and adequately compensate shareholders in light of SeraCare's recent first quarter 2012 results. Significantly, the deal represents only an 11.73% premium, well below an average premium of 72.99% over the past two years for comparable transactions in the "Medical Products" sector. In addition, on February 10, 2012, the company reported EPS of $0.07 on revenue of $11.37 million while analysts polled by Bloomberg had been expecting EPS of $0.03 on revenue of $11.00 million. Further, the company's first quarter 2012 revenue of $11.37 million represented a 9% increase compared with the $10.5 million reported for the same quarter in the prior year. Moreover, gross margins increased 6% to 44%, compared with 38% for the same quarter in the prior year. Finally, at least two market analysts have released target prices for SeraCare that value the company's stock at $5.00 per share, higher than the value being offered by Linden Capital Partners as a part of the proposed transaction.

Robbins Umeda attorneys highlight that SeraCare shareholders have the option to file a class action lawsuit against the company to secure the best possible price for the company's shareholders and the disclosure of material information to shareholders so they can vote on the transaction in an informed manner.

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com.

Press release link: http://www.robbinsumeda.com/shareholders-rights-blog/seracare/

Attorney Advertising. Past results do not guarantee a similar outcome.

(c) 2014 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
Back to SRLS
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki